Source:http://linkedlifedata.com/resource/pubmed/id/12919746
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2003-8-15
|
pubmed:abstractText |
A mouse-adapted strain of Ebola Zaire virus produces a fatal infection when BALB/cj mice are infected intraperitoneally (ip) but subcutaneous (sc) infection with the same virus fails to produce illness and confers long-term protection from lethal ip rechallenge. To identify immune correlates of protection in this model, we compared viral replication and cytokine/chemokine responses to Ebola virus in mice infected ip (10 PFU/mouse), or sc (100 PFU/mouse) and sc "immune" mice rechallenged ip (10(6) PFU/mouse) at several time points postinfection (pi). Ebola viral antigens were detected in the serum, liver, spleen, and kidneys of ip-infected mice by day 2 pi, increasing up to day 6. Sc-infected mice and immune mice rechallenged ip had no detectable viral antigens until day 6 pi, when low levels of viral antigens were detected in the livers of sc-infected mice only. TNF-alpha and MCP-1 were detected earlier and at significantly higher levels in the serum and tissues of ip-infected mice than in sc-infected or immune mice challenged ip. In contrast, high levels of IFN-alpha and IFN-gamma were found in tissues within 2 days after challenge in sc-infected and immune mice but not in ip-infected mice. Mice became resistant to ip challenge within 48 h of sc infection, coinciding with the rise in tissue IFN-alpha levels. In this model of Ebola virus infection, the nonlethal sc route of infection is associated with an attenuated inflammatory response and early production of antiviral cytokines, particularly IFN-alpha, as compared with lethal ip infection.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0042-6822
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
312
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
415-24
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:12919746-Animals,
pubmed-meshheading:12919746-Antigens, Viral,
pubmed-meshheading:12919746-Disease Models, Animal,
pubmed-meshheading:12919746-Ebolavirus,
pubmed-meshheading:12919746-Female,
pubmed-meshheading:12919746-Hemorrhagic Fever, Ebola,
pubmed-meshheading:12919746-Immunity, Innate,
pubmed-meshheading:12919746-Inflammation,
pubmed-meshheading:12919746-Kidney,
pubmed-meshheading:12919746-Liver,
pubmed-meshheading:12919746-Mice,
pubmed-meshheading:12919746-Mice, Inbred BALB C,
pubmed-meshheading:12919746-Spleen,
pubmed-meshheading:12919746-Survival Rate
|
pubmed:year |
2003
|
pubmed:articleTitle |
Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection.
|
pubmed:affiliation |
Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Centers for Infectious Diseases, Centers for Disease Control & Prevention, Atlanta, GA 30333, USA. smahanty@niaid.nih.gov
|
pubmed:publicationType |
Journal Article
|